The PROSPECT II study was published in the March 13th issue of The Lancet,
finding that IVUS+NIRS imaging can detect plaques at increased risk for future adverse cardiac outcomes.VIEW ARTICLE VIEW ARTICLE

Infraredx, a Nipro Company, and B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc., Announce Strategic U.S. Collaboration to Execute the IDE Clinical Trial for the SeQuent® Please ReX™ Drug Coated PTCA Balloon Catheter.

READ MORE

Globally, cardiovascular disease is the leading cause of death, killing more than 17 million people each year, with deaths projected to continue to rise. Nearly half (42%) of deaths associated with cardiovascular disease are due to coronary artery disease.1

Plaque Rupture: A Major Cause of Heart Attacks

While heart attacks are usually caused by the narrowing or complete blockage of the coronary artery due to plaque buildup, plaque can also break loose, causing a clot blockage large enough to trigger a heart attack.

Different plaques have different composition, and not all plaques are prone to rupture. Fibrotic, or calcified, plaques, are more stable and less prone to rupture. Lipid Core Plaques (LCP), on the other hand, have thin fibrous caps, making them vulnerable to rupture.

Identifying Dangerous Plaques Can Improve Prognosis

Distinguishing between plaques of different composition is crucial for accurately predicting and managing a patient’s risk of new or recurring cardiovascular events. Near-Infrared Spectroscopy, or NIRS, technology can help interventional cardiologists determine not only a plaque’s structure, but its composition as well. The ability to identify dangerous plaques can help clinicians improve the prognosis of high-risk patients.

Discover IVUS+NIRS

Learn More

1. https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

© 2020 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative